Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer

Gastric Cancer Clinical Trial

— DCXAIOCHARITE  

Official title:

Multicenter, Open Lable Phase II Study to Evaluate the Safety and Efficacy of a Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine in Patients With Gastric Adenocarcinoma, Adenocarcinoma of the Gastro-esophageal Junction or the Distal Esophagus

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00865982
• Other study ID #: Eudract-CT-2008-001849-26
• Status: Active, not recruiting
• Phase: Phase 2
• First received: March 19, 2009
• Last updated: August 4, 2011
• Start date: September 2008
• Est. completion date: September 2015

Study information

• Verified date: August 2011
• Source: Charite University, Berlin, Germany
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

In this study, patients with adenocarcinoma of the stomach, gastro-esophageal junction or the distal esophagus who seem operable with curative intent according to oncological and surgical assessment are treated with 3 preoperative cycles of DCX (Docetaxel, Cisplatin, Capecitabine) followed by surgical resection, followed by 3 postoperative cycles of DCX.

Description:

Perioperative chemotherapy has been shown to significantly improve the R0 resection rate, the disease free survival and the overall survival in patients with adenocarcinoma of the distal esophagus, the gastro-esophageal junction and the stomach. Therefore perioperative chemotherapy is the new therapeutic standard (Cunningham NEJM 2006, MRC, Lancet 2002, Boige ASCO 2007). The best evaluated regime is the combination of Epirubicin, Cisplatin and 5-FU (ECF) (Cunningham, NEJM 2007). Cisplatin and 5-FU seem to be the most important components forming the backbone of this regime (Boige ASCO 2007).

Docetaxel is a new and highly active agent in gastric cancer. In a randomized phase II study the dual combination of Docetaxel and 5-FU seemed to show similar activity as ECF, administered as first line palliative treatment (Thuss-Patience, JCO, 2005). The three drug combination Docetaxel, Cisplatin, 5-FU has significantly superior efficacy than a combination of Cisplatin und 5-FU, superior quality of life and significantly superior overall survival (Van Cutsem, JCO 2007).

It has been shown that Capecitabine the oral prodrug of 5-FU is similarly active as 5-FU and can replace intravenous 5-FU in combination with Cisplatin in the treatment of gastric cancer. Capecitabine therefore is FDA approved for gastric cancer (Cunningham, ASCO 2006, Kang ASCO 2006).

It seems reasonable to optimize perioperative chemotherapy by including modern chemotherapeutics. The old standard ECF may be improved by integrating Docetaxel und Capecitabine. By adding Docetaxel to the Cisplatin / flouropyrimidin backbone the efficacy of the regime may be improved. The replacement of 5-FU by Capecitabine may improve patients´ convenience and possibly effectiveness of the combination. Therefore the 3 drug combination of Docetaxel, Cisplatin, Capecitabin (DCX) seems to be a highly promising regime regarding effectiveness and convenience.

In this study patients with adenocarcinoma of the stomach, gastro-esophageal junction or the distal esophagus who seem operable with curative intent according to oncological and surgical assessment are treated with 3 preoperative cycles of DCX followed by surgical resection, followed by 3 postoperative cycles of DCX.

The first application of study medication has to be within 21 days of tumour assessment. There will be 3 preoperative cycles every 3 weeks. The experimental perioperative regime evaluated in this study will be Docetaxel/Cisplatin/Capecitabine DCX (75/ 60/ 1875 mg/m2).The operation will be performed 3 to 6 weeks after the end of the third preoperative chemotherapy cycle (counted from day 21 of cycle 3).

Postoperative chemotherapy will start within 6 - 12 weeks after the operation. 3 weeks after the end of the last chemotherapy the final investigation (end of study visit) will be done.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 50
• Est. completion date: September 2015
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Signed and dated consent

• Age between minimum 18 and maximum 75 years

• Primary diagnosis of histologically proven adenocarcinoma of the stomach, the gastro-esophageal junction or an adenocarcinoma of the lower third of the esophagus

• Stage II-III, which is in TNM-staging: T3-4, N0-3, M0 or T2, N1-3, M0 or T1, N2, M0. (equivalent to clinical staging uT3-4NXM0, uT1-2N+M0)

• Intended curative resection according to evaluation of an experienced surgeon

• Karnofsky-performance-index > 70%

• Negative pregnancy blood test at screening but not earlier than 72 hours prior to start of chemotherapy for women with child bearing potential

• Adequate haematologic function and liver and renal function: neutrophils > 1,5 x 109/L; thrombocytes > 100 x 109/L; haemoglobin > 10 g/dl, creatinine clearance > 60 ml/min (calculated according to Cockroft and Gault), total bilirubin < 1,0 x UNL; AST and ALT < 1,5 x UNL, AP < 2,5 x UNL

• Complete staging within 3 weeks prior to start of treatment (CT-scan of thorax and abdomen, endosonography, gastroscopy)

• Ability to keep appointments and follow the study protocol

• By CT-scan, endoscopy or endosonography measurable or evaluable disease

Exclusion Criteria:

• Former therapy of gastro-esophageal cancer (operation, chemo- or radiotherapy)

• Diagnosis of another cancer in the last 5 years prior to study entry which has not been cured by operation only (exception in-situ-carcinoma of the cervix or cured non-melanomatose skin cancer)

• Known dihydropyrimidine-dehydrogenase (DPD)-deficiency

• Known contraindication to the planned chemotherapeutics

• Presence of distant metastases

• Anamnestic known serious disease or other concomitant diseases that affect participation in this study, such as:

• Instable cardiac disease: symptomatic heart failure, symptomatic coronary artery disease, ventricular cardiac arrhythmia not well controlled with medication, myocardial infarction or resuscitation within 6 month before study

• Active infection necessitating systemic therapy or uncontrolled infection

• Interstitial lung diseases (for example: pneumonitis or fibrosis of the lung) and indication for interstitial lung disease in chest x-ray or CT-scan respectively

• Active inflammatory bowel disease or other bowel diseases which provoke chronic diarrhea (defined as > 4 bowel movements per day)

• Neurological or psychiatric disease including dementia, epilepsy or untreated, symptomatic brain metastases

• Limited hearing ability

• Presence of upper GI obstruction, leading to inability to swallow ground tablets

• Presence of acute or chronic systemic infection

• Presence of a bowel obstruction within the last 30 days

• Pregnant or lactating women or women with child bearing potential and men without adequate contraception (high effective contraception, defined as Pearl Index < 1) like birth control pill, hormone spiral, hormone implant, transdermal patch, a combination of two barrier methods (condom and diaphragm), realized sterilization or sexual abstinence during the study and at least for 3 months after the last infusion

• Any other situation which may lead to an unacceptable high risk for the patient, when he participates in the study

• Parallel treatment in another clinical study or prior participation in this study

• Treatment with any other therapy against the tumor or any parallel radiation

• Parallel treatment with Sorivudine or an chemically related substance like for example Brivudin

• Symptomatic peripheral neuropathy NCI-CTCAE degree > 2

• Intolerance to the study medication or their galencic ingredients or against 5-FU

• Detention in a psychiatric unit or imprisonment (AMG §40 Abs. 1 Nr. 4)

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms
• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Docetaxel, Cisplatin, Capecitabine
3 preoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks followed by resection and 3 postoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks.

Locations

Country	Name	City	State
Germany	HELIOS-Klinik Bad Saarow	Bad Saarow
Germany	Klinik für Hämatologie, Onkologie und Tumorimmunologie, Charite Campus Buch	Berlin
Germany	Medizinische Klinik mit Schwerpunkt Gastroenterologie, Infektiologie und Rheumatologie, Charite Campus Benjamin-Franklin	Berlin
Germany	Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charite Campus Virchow Klinikum	Berlin
Germany	Klinik für Innere Medizin Abteilung Hämatologie/Onkologie, Städtisches Klinikum Dessau	Dessau
Germany	Universitätsklinik und Poliklinik für Innere Medizin IV, Martin Luther Universität Halle-Wittenberg	Halle (Saale)
Germany	II. Medizinische Klinik und Poliklinik, Universitätsklinikum Schleswig-Holstein Campus Kiel	Kiel
Germany	Internistische Onkologie/ Hämatologie, Städtisches Krankenhaus St. Georg	Leipzig
Germany	3. Medizinische Klinik, Onkologisches Zentrum, Universitätsklinikum Mannheim	Mannheim

Sponsors (3)

Lead Sponsor	Collaborator
Charite University, Berlin, Germany	Roche Pharma AG, Sanofi

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	R0-resection rate		After 3 cycles of preoperative chemotherapy (3 month)	No
Secondary	Remission rate according to diagnostic imaging techniques		After 3 cycles of preoperative chemotherapy (3 month)	No
Secondary	Pathological remission rate		After 3 cycles of preoperative chemotherapy (3 month)	No
Secondary	Operative and postoperative complication rate		Within 30 days after surgery	Yes
Secondary	Resectability rate		After 3 cycles of preoperative chemotherapy (3 month)	No
Secondary	Rate of local recurrences and metastasis			No
Secondary	Toxicity			Yes
Secondary	30-day mortality		After date of surgery	Yes
Secondary	Overall survival			No
Secondary	Overall survival rate		1,2,3 and 5 years	No
Secondary	Event free survival rate			No